Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivir strengthens management team

This article was originally published in Scrip

Executive Summary

Medivir, a research-based speciality pharma company focused on infectious diseases, has made several new appointments to its management team. Dr Maris Hartmanis joins the company as deputy CEO and COO, but will continue to work as CEO of Biophausia, which was recently acquired by Medivir. Professor Bertil Samuelsson, previously chief scientific officer, has been appointed chief scientific advisor focusing his efforts on the strategic development of Medivir's R&D. Dr Charlotte Edenius, previously vice-president of R&D, takes on the role of executive vice-president of R&D, and Dr Jens Kristensen has been appointed executive vice-president of the company's clinical unit. Dr Kristensen most recently served as vice-president of Karo Bio.

Advertisement
Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014279

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel